Connect
MJA
MJA

Bevacizumab and hereditary haemorrhagic telangiectasia

Ross P Cruikshank and Boris W Chern
Med J Aust 2011; 194 (6): . || doi: 10.5694/j.1326-5377.2011.tb02989.x
Published online: 21 March 2011

To the Editor: Hereditary haemorrhagic telangiectasia (HHT) or Osler–Weber–Rendu syndrome manifests as vascular dysplasia involving the nose, skin, lung, brain and gastrointestinal tract. It is an inherited disorder manifesting as unbalanced angiogenesis.1


  • Redcliffe Hospital, Brisbane, QLD.


Correspondence: rosscruikshank@yahoo.com

  • 1. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
  • 2. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased levels of vascular endothelial growth factor and transforming growth factor-b1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
  • 3. Bose P, Holter J, Selby G. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-2144.
  • 4. Oosting S, Nagengast W, de Vries E. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361: 931.
  • 5. Mitchell A, Adams L, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14: 210-213.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.